Neil Crabb, chief executive of Frontier IP Group Plc (LON:FIPP) caught up with Proactive's Andrew Scott following the release of their half-year report.
Frontier's portfolio includes AI drug researcher Exscientia which secured a ?,?15mln strategic investment from drug discovery company Evotec while foodtech company Nandi Protein raised ?1mln in the period.
Crabb says they're seeing strong interest across the board in their its portfolio which he reckons reflects the success of their strategy to take stakes in companies which are at a very early stage of the commercialisation process.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>